DIAGNOSTIC TEST 874
ANNA-3 Antibodies
Diagnostic test for antibodies against ANNA-3. For paraneoplastic syndromes.
Indication
Suspicion of paraneoplastic neoplastic syndrome
Sample material
Serum
- Minim. volume: 0,5 mL
CSF
- Minim. volume: 0,5 mL
Transport
- Within Sweden: room temperature
- International: cold
Method
Indirect immunofluorescence (IIF)
Reference interval
Serum: <1:20 negative
CSF: <1:2 negative
Result
Results are reported as negative or positive. A positive result is followed by a titer (serum).
Interpretation
ANNA-3 is strongly associated with small cell lung cancer (SCLC) but has also been reported in adenocarcinoma. ANNA-3 is associated with sensory-motor neuropathy with or without ataxia, cerebellar ataxia, and brainstem encephalitis.
The antibodies may be present along with other paraneoplastic markers such as anti-Ri/Nova1 and calcium channel antibodies (VGCC).
References
- Banks SA et al. Ther Adv Neurol Disord. 2021. Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. PMID: 33796145
- Gilligan M et al. Clin Biochem. 2024. Autoimmune central nervous system disorders: Antibody testing and its clinical utility. PMID: 38462203
Included in these panels
Need pricing information?
How to order
This test is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
Serum: At least 0.5 mL serum (plain serum tubes without additives).
CSF: At least 0.5 mL CSF (polypropylene tubes).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples cold to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-12-05
